Journal of Vaccines & Vaccination

Abstract

Peptide-mRNA Vaccine for SARS-Cov-2

Esmaeil Farshi*

A vaccine is described which elicits a protective immune response against SARS-Cov-2. Designed engineered peptides that could strongly bind to the spike protein of coronavirus inside cells, and to use these peptides to trigger the cells to break down the viral proteins. In this vaccine the mRNA (encoding Ribonucleic Acid) encodes a stable perfused form (the form before being fused to the cell membrane of the host cell) of Spike protein (S). In this vaccine the main problem of short time remaining of antibodies of SARS-Cov-2 virus in body could be compensated by activation of T cells that causes long term immunity because memory T cells remain in body at least 11 years. A peptide based vaccine with encoding mRNA of virus along the activation of T cells through MHC class-II which elicits protection against SARS-Cov-2 through immune cells from the lymph nodes process the mRNA and synthesize specific viral protein antigens so that other immune cells recognize them. In this vaccine that comprising peptide encoding mRNA along activation of T cells by MHC class-II which immunize body against SARS-Cov-2 are also described. Methods of protecting a host against coronavirus infection will be discussed. Our invented vaccine is type of mRNA vaccine (but combined with other components) against SARS-COV-2 is based on a relatively new genetic method that does not require growing the virus in the laboratory. The technique transforms the human body into a 'living laboratory'. Monkeys given our coronavirus vaccine and then deliberately infected were able to fight off the virus, quickly clearing it from their lungs.

Published Date: 2020-10-24; Received Date: 2020-09-03